Author:
Jackson William C.,Feng Felix Y.,Daignault Stephanie,Hussain Maha,Smith David,Cooney Kathleen,Pienta Kenneth,Jolly Shruti,Hollenbeck Brent,Olson Karin B.,Sandler Howard M.,Ray Michael E.,Hamstra Daniel A.
Subject
Radiology, Nuclear Medicine and imaging,Oncology
Reference27 articles.
1. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience;Han;Urol Clin North Am,2001
2. Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy;Jackson;Cancer,2013
3. Christopher S, Chen Y.-H, Carducci MA, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. ASCO Annual Meeting, 2014; Chicago, IL.
4. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004
5. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004